Literature DB >> 26838018

The Cobas® EGFR Mutation Test v2 assay.

Paul Brown1.   

Abstract

Paul Brown speaks to Gemma Westcott, Commissioning Editor: Paul Brown has served as the Head of Roche Molecular Diagnostics at Roche Diagnostics Corporation since February 2010 having previously held a variety of positions within Roche Pharma. After completing his doctorate in organic chemistry he was awarded a post-doctoral fellowship at the California Institute of Technology in Pasadena, CA, USA, but soon returned to his native UK to join Roche Pharma Research. Paul's first post within Roche was as group leader, doing drug discovery and making new small molecule drugs, but later moved into the business part of the company. Since then, he has enjoyed roles such as lifecycle leader for brands such as Tamiflu(®) and Xenical, vice president of sales and marketing of the pharmaceutical division and most recently general manager of Roche Pharma, Sweden.

Entities:  

Keywords:  Cobas® EGFR Mutation Test v2; in vitro diagnostics; lung cancer; oncology

Mesh:

Substances:

Year:  2016        PMID: 26838018     DOI: 10.2217/fon.15.311

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  18 in total

1.  Kinetic analysis, size profiling, and bioenergetic association of DNA released by selected cell lines in vitro.

Authors:  Janine Aucamp; Abel J Bronkhorst; Dimetrie L Peters; Hayley C Van Dyk; Francois H Van der Westhuizen; Piet J Pretorius
Journal:  Cell Mol Life Sci       Date:  2017-03-18       Impact factor: 9.261

2.  Microfluidics in Malignant Glioma Research and Precision Medicine.

Authors:  Meghan Logun; Wujun Zhao; Leidong Mao; Lohitash Karumbaiah
Journal:  Adv Biosyst       Date:  2018-04-02

Review 3.  Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas.

Authors:  Anudeep Yekula; Koushik Muralidharan; Zachary S Rosh; Anna E Youngkin; Keiko M Kang; Leonora Balaj; Bob S Carter
Journal:  Adv Biosyst       Date:  2020-06-02

Review 4.  Circulating Tumor DNA as Biomarkers for Cancer Detection.

Authors:  Xiao Han; Junyun Wang; Yingli Sun
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-04-07       Impact factor: 7.691

Review 5.  Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis.

Authors:  Mona Mlika; Chadli Dziri; Mohamed Majdi Zorgati; Mehdi Ben Khelil; Faouzi Mezni
Journal:  Curr Respir Med Rev       Date:  2018-03

6.  High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer.

Authors:  Wenwu Xiao; Weijie Ma; Sixi Wei; Qianping Li; Ruiwu Liu; Randy P Carney; Kevin Yang; Joyce Lee; Alan Nyugen; Ken Y Yoneda; Kit S Lam; Tianhong Li
Journal:  J Hematol Oncol       Date:  2019-06-10       Impact factor: 17.388

7.  EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.

Authors:  Anna Buder; Ulrike Setinek; Maximilian J Hochmair; Sophia Schwab; Klaus Kirchbacher; Andrea Keck; Otto C Burghuber; Robert Pirker; Martin Filipits
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

Review 8.  Liquid Biopsy in Uveal Melanoma: Are We There Yet?

Authors:  Eva Jin; Julia V Burnier
Journal:  Ocul Oncol Pathol       Date:  2020-07-29

9.  Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.

Authors:  Lori E Lowes; Scott V Bratman; Ryan Dittamore; Susan Done; Shana O Kelley; Sabine Mai; Ryan D Morin; Alexander W Wyatt; Alison L Allan
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

Review 10.  Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management.

Authors:  Maha Elazezy; Simon A Joosse
Journal:  Comput Struct Biotechnol J       Date:  2018-10-09       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.